Neuphoria Therapeutics Inc.
Business
Neuphoria Therapeutics is a clinical-stage biotechnology company developing therapies for neuropsychiatric disorders, with BNC210, an oral selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, in Phase 3 trials for acute social anxiety disorder and chronic post-traumatic stress disorder. The company also has a partnership with Merck for α7 receptor positive allosteric modulators targeting cognitive impairment in Alzheimer's disease, preclinical ion-channel programs, and legacy oncology assets licensed to external partners. Neuphoria operates as a single clinical-stage company advancing multiple CNS-focused development programs toward potential FDA approval and commercialization.
Summary from 10-K filed 2025-09-29
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 |
|---|---|---|---|---|
| License revenue | 16 | — | — | |
| Research and development | 9 | 9 | 13 | |
| General and administrative | 8 | 8 | 9 | |
| Total operating expenses | 17 | 18 | 22 | |
| Loss from operations | −1 | −18 | −22 | |
| Interest income, net | 166,498 | 220,097 | 323,158 | |
| Loss on foreign currency transactions | −414,996 | −209,842 | 308,852 | |
| Research and development incentive award | 299,905 | 95,215 | 422,742 | |
| Gain on fair value adjustments | 239,686 | 2 | −592,627 | |
| Total other income | 291,093 | 2 | 462,125 | |
| Loss before income tax benefit | −837,998 | −16 | −22 | |
| Income tax benefit | 468,366 | 87,320 | 139,174 | |
| Net loss | −400,000 | −16 | −21 | |
| Unrealized gain on foreign currency translation | 168,529 | 45,188 | −1 | |
| Total other comprehensive income | 168,529 | 45,188 | −1 | |
| Total comprehensive loss | −201,103 | −15 | −22 | |
| Net loss per share - basic | −0.23 | −18.62 | −0.02 | |
| Net loss per share - diluted | −0.23 | −18.62 | −0.02 | |
| Weighted-average common shares outstanding - basic | 2 | 832,225 | 1,469 | |
| Weighted-average common shares outstanding - diluted | 2 | 832,225 | 1,469 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 14 | 13 | 12 | — | |
| Accounts receivable, non-trade | 11,948 | 126,884 | 426,087 | — | |
| Restricted cash | 77,945 | — | — | — | |
| Prepaid expenses | 740,193 | 458,765 | 797,478 | — | |
| Total current assets | 15 | 13 | 13 | — | |
| Property and equipment, net | 2,771 | 1,994 | 2,522 | — | |
| Intangible assets, net | 5 | 5 | 6 | — | |
| Operating lease right-of-use assets | 102,612 | 216,975 | 330,478 | — | |
| Restricted cash | — | 78,826 | 78,897 | — | |
| Goodwill | 9 | 9 | 9 | 9 | |
| Total assets | 29 | 28 | 29 | — | |
| Accounts payable | 1 | 2 | 1 | — | |
| Accrued expenses and other current liabilities | 3 | 1 | 1 | — | |
| Operating lease liability | 116,314 | 121,990 | 113,930 | — | |
| Total current liabilities | 4 | 4 | 3 | — | |
| Operating lease liability, net of current portion | — | 117,628 | 239,835 | — | |
| Contingent consideration | 1 | 587,762 | 2 | — | |
| Deferred tax liability | 495,113 | 963,540 | 1 | — | |
| Accompanying warrant liability | 4 | 5 | — | — | |
| Other non-current liabilities | — | 2,886 | 14,850 | — | |
| Total liabilities | 10 | 10 | 7 | — | |
| Commitments and contingencies | — | — | — | — | |
| Common stock, $0.00001 par value, 1,978,460 and 1,103,954 shares issued and outstanding at June 30, 2025 and 2024, respectively | 19 | 11 | — | — | |
| Additional paid in capital, net of subscription receivable | 200 | 198 | 188 | — | |
| Accumulated other comprehensive loss, net of tax | −3 | −3 | −3 | — | |
| Accumulated deficit | −178 | −178 | −162 | — | |
| Total shareholders equity | 19 | 17 | 22 | 39 | |
| Total liabilities and shareholders equity | 29 | 28 | 29 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 |
|---|---|---|---|---|
| Share-based compensation | 163,772 | 814,808 | 1 | |
| Depreciation and amortization expense | 662,890 | 662,991 | 663,192 | |
| Non-cash rent expense | 114,363 | 113,503 | 115,123 | |
| Change in fair value of accompanying warrant liability | −956,340 | −338,983 | — | |
| Change in fair value of contingent consideration | 716,654 | −2 | 592,627 | |
| Effect of foreign currency remeasurement | 242,348 | −27,350 | −556,782 | |
| Accounts receivable, non-trade | 114,936 | 299,203 | 4 | |
| Prepaid expenses | −453,058 | 338,713 | — | |
| Accounts payable | −917,663 | 804,371 | 374,176 | |
| Accrued expenses and other current liabilities | 1 | 277,854 | 138,079 | |
| Operating lease liabilities | −123,304 | −114,147 | −107,808 | |
| Deferred tax liability | −468,427 | −139,173 | −139,173 | |
| Contingent consideration | −133,080 | — | — | |
| Other non-current liabilities | −2,886 | −11,964 | 8,041 | |
| Net cash provided by (used in) operating activities | 100,000 | −15 | −15 | |
| Proceeds from the sale of equity, net of subscriptions receivable and issuance costs | 2 | 10 | — | |
| Proceeds from the sale of accompanying warrant | — | 5 | — | |
| Net cash provided by financing activities | 2 | 15 | 4 | |
| Effect of exchange rate on changes on cash, cash equivalents, and restricted cash | −3,750 | 76,974 | −243,822 | |
| Net increase in cash, cash equivalents, and restricted cash | 2 | 504,991 | — | |
| Cash paid for interest expense | 17,433 | 31,516 | — | |
| Cash paid for income tax expense | — | 51,853 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Neuphoria Therapeutics Inc.'s CIK number?
Neuphoria Therapeutics Inc.'s SEC CIK number is 0001191070 (1191070). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Neuphoria Therapeutics Inc.'s SEC filings?
All of Neuphoria Therapeutics Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Neuphoria Therapeutics Inc. last report earnings?
Neuphoria Therapeutics Inc. (NEUP) most recently filed an earnings 8-K with the SEC on May 20, 2025, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001213900-25-045970). This is Neuphoria Therapeutics Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Neuphoria Therapeutics Inc.'s most recent earnings 8-K?
Neuphoria Therapeutics Inc.'s latest earnings 8-K (Item 2.02) was filed May 20, 2025 under accession 0001213900-25-045970. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Neuphoria Therapeutics Inc.'s latest earnings 8-K →
Look up any company's CIK number →